Blood-stage malaria vaccines — recent progress and future challenges

The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response

(2014) G. B. Rohner et al.   JOURNAL OF IMMUNOLOGY

Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment of Plasmodium falciparum Merozoite Surface Protein-1 in Vaccinated Volunteers

(2014) M. C. Huaman et al.   JOURNAL OF IMMUNOLOGY

Vaccination with Live Plasmodium yoelii Blood Stage Parasites under Chloroquine Cover Induces Cross-Stage Immunity against Malaria Liver Stage

(2014) E. Belnoue et al.   JOURNAL OF IMMUNOLOGY

Improving vaccine delivery using novel adjuvant systems

(2011) Michael E. Pichichero   Human vaccines & immunotherapeutics

The role ofPlasmodium falciparumvariant surface antigens in protective immunity and vaccine development

(2010) Lars Hviid   Human vaccines & immunotherapeutics

Current status ofPlasmodium vivaxvaccine

(2010) Myriam Arévalo-Herrera et al.   Human vaccines & immunotherapeutics

Prime-boost vectored malaria vaccines: Progress and prospects

(2010) Adrian V. S. Hill et al.   Human vaccines & immunotherapeutics

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

(2010) Mark A. Pierce et al.   VACCINE

Distinct External Signals Trigger Sequential Release of Apical Organelles during Erythrocyte Invasion by Malaria Parasites

(2010) Shailja Singh et al.   PLoS Pathogens

Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria

(2009) Simon J. Draper et al.   Cell Host & Microbe

Inhibitory Antibodies Specific for the 19-Kilodalton Fragment of Merozoite Surface Protein 1 Do Not Correlate with Delayed Appearance of Infection with Plasmodium falciparum in Semi-Immune Individuals in Vietnam

(2009) E. E. H. Murhandarwati et al.   INFECTION AND IMMUNITY

Growth-Inhibitory Antibodies Are Not Necessary for Protective Immunity to Malaria Infection

(2009) E. E. H. Murhandarwati et al.   INFECTION AND IMMUNITY

Atypical Memory B Cells Are Greatly Expanded in Individuals Living in a Malaria-Endemic Area

(2009) G. E. Weiss et al.   JOURNAL OF IMMUNOLOGY

Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

(2009) John PA Lusingu et al.   MALARIA JOURNAL

Initiative targets malaria eradication

(2009) Declan Butler   NATURE

Viruses as vaccine vectors for infectious diseases and cancer

(2009) Simon J. Draper et al.   NATURE REVIEWS MICROBIOLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection against a Malaria Challenge by Sporozoite Inoculation

(2009) Meta Roestenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Viral vectors in malaria vaccine development

(2009) K. J. LIMBACH et al.   PARASITE IMMUNOLOGY

Adjuvants for malaria vaccines

(2009) R. N. COLER et al.   PARASITE IMMUNOLOGY

The development of the RTS,S malaria vaccine candidate: challenges and lessons

(2009) W. R. BALLOU   PARASITE IMMUNOLOGY

Fc-receptors and immunity to malaria: from models to vaccines

(2009) R. J. PLEASS   PARASITE IMMUNOLOGY

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso

(2009) I. NEBIE et al.   PARASITE IMMUNOLOGY

The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria

(2009) A. A. HOLDER   PARASITOLOGY

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

(2009) Michele D. Spring et al.   PLoS One

A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli

(2009) Debabani Roy Chowdhury et al.   PLoS One

Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children

(2009) Sodiomon B. Sirima et al.   PLoS One

Vaccinating with the genome: a Sisyphean task?

(2009) Ross L. Coppel   TRENDS IN PARASITOLOGY

Report of a Consultation on the Optimization of Clinical Challenge Trials for Evaluation of Candidate Blood Stage Malaria Vaccines, 18–19 March 2009, Bethesda, MD, USA

(2009) V.S. Moorthy et al.   VACCINE

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

(2009) Issaka Sagara et al.   VACCINE

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

(2009) Issaka Sagara et al.   VACCINE

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys

(2009) S. Pichyangkul et al.   VACCINE

The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali

(2009) Boubacar Traore et al.   VACCINE

Functional Analysis of the Leading Malaria Vaccine Candidate AMA-1 Reveals an Essential Role for the Cytoplasmic Domain in the Invasion Process

(2009) Moritz Treeck et al.   PLoS Pathogens

Functional Memory B Cells and Long-Lived Plasma Cells Are Generated after a Single Plasmodium chabaudi Infection in Mice

(2009) Francis Maina Ndungu et al.   PLoS Pathogens

Transgenic RodentPlasmodium bergheiParasites as Tools for Assessment of Functional Immunogenicity and Optimization of Human Malaria Vaccines

(2008) Godfree Mlambo et al.   EUKARYOTIC CELL

Malaria vaccines: the case for a whole-organism approach

(2008) Alberto Pinzon-Charry et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Murine Model for Assessment of Plasmodium falciparum Transmission-Blocking Vaccine Using Transgenic Plasmodium berghei Parasites Expressing the Target Antigen Pfs25

(2008) G. Mlambo et al.   INFECTION AND IMMUNITY

Effective induction of high-titer antibodies by viral vector vaccines

(2008) Simon J Draper et al.   NATURE MEDICINE

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

(2008) Salim Abdulla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults

(2008) Jinhong Hu et al.   PLoS One

New horizons in adjuvants for vaccine development

(2008) Steven G. Reed et al.   TRENDS IN IMMUNOLOGY

Apical membrane antigen 1: a malaria vaccine candidate in review

(2008) Edmond J. Remarque et al.   TRENDS IN PARASITOLOGY

The end of the beginning: Vaccines for the next 25 years

(2008) J.S. Oxford   VACCINE

A Phase 1 trial of PfCP2.9: An AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

(2008) Elissa Malkin et al.   VACCINE

Taking social relationships seriously: Lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast

(2008) Caroline Gikonyo et al.   SOCIAL SCIENCE & MEDICINE